title: Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer.
abstract: The malignant behaviors of solid tumors such as growth, infiltration and metastasis are mainly nourished by tumor neovascularization. Thus, anti-angiogenic therapy is key to controlling tumor progression. Bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) antibody, plus chemotherapy or biological therapy can prolong survival for cancer patients, but treatment-related mortality is a concern. To improve inhibitory effect and decrease side-effects on non-small-cell lung cancer (NSCLC), we used Re-188, which is a β emitting radionuclide, directly labeled with bevacizumab for radioimmunotherapy in a human A549 tumor model. Cytotoxic assay data showed that, after188ReO₄-or188Re-bevacizumab at different concentration for 4 and 24 h, a time- and radioactivity does-dependent reduction in cell viability occurred. Also, an apoptosis assay conformed great apoptosis in the188Re-bevacizumab group compared with controls and other treatment groups. In vivo, tumor volumes in the188Re-bevacizumab (11.1 MBq/mice) group were not reduced but growth was delayed compared with other groups. Thus,188Re-bevacizumab enhanced the therapeutic effect of bevacizumab, suggesting a potential therapeutic strategy for NSCLC treatment.
authors.affiliation: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. xiaojie_fdu@163.com.|Shanghai Institute of Medical Imaging, Shanghai 200032, China. xiaojie_fdu@163.com.
authors.forename: Jie
authors.initials: J
authors.lastname: Xiao
authors.affiliation: Departments of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. xu.xiaobo@zs-hospital.sh.cn.
authors.forename: Xiaobo
authors.initials: X
authors.lastname: Xu
authors.affiliation: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. leelobster@126.com.|Shanghai Institute of Medical Imaging, Shanghai 200032, China. leelobster@126.com.
authors.forename: Xiao
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. drliyanli@163.com.|Shanghai Institute of Medical Imaging, Shanghai 200032, China. drliyanli@163.com.
authors.forename: Yanli
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. liuguobing0422@163.com.|Shanghai Institute of Medical Imaging, Shanghai 200032, China. liuguobing0422@163.com.
authors.forename: Guobing
authors.initials: G
authors.lastname: Liu
authors.affiliation: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. 13818914579@163.com.|Shanghai Institute of Medical Imaging, Shanghai 200032, China. 13818914579@163.com.
authors.forename: Hui
authors.initials: H
authors.lastname: Tan
authors.affiliation: Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 200032, China. shenhua@sinap.ac.cn.
authors.forename: Hua
authors.initials: H
authors.lastname: Shen
authors.affiliation: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. shihongcheng163@163.com.|Shanghai Institute of Medical Imaging, Shanghai 200032, China. shihongcheng163@163.com.
authors.forename: Hongcheng
authors.initials: H
authors.lastname: Shi
authors.affiliation: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. cheng.dengfeng@zs-hospital.sh.cn.|Shanghai Institute of Medical Imaging, Shanghai 200032, China. cheng.dengfeng@zs-hospital.sh.cn.
authors.forename: Dengfeng
authors.initials: D
authors.lastname: Cheng
mesh_terms: D000068258:Bevacizumab / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D011868:Radioisotopes / Q000494:pharmacology*; D012211:Rhenium / Q000494:pharmacology*
chemical_list: D011868:Radioisotopes; D000068258:Bevacizumab; D012211:Rhenium
keywords: Re-188; Tc-99m; bevacizumab; non-small cell lung cancer; radioimmunotherapy